Background. Triple-negative breast cancer is an aggressive subtype of breast cancer with high recurrence rate and poor prognosis. Here we describe a novel, genetically engineered parapoxvirus that efficiently kills triple-negative breast cancer. Methods. A novel chimeric parapoxvirus (CF189) was generated via homologous recombination and identified through high-throughput screening. Cytotoxicity was assayed in vitro in 4 triple-negative breast cancer cell lines. Viral replication was examined through standard plaque assay. Orthotopic triplenegative breast cancer xenografts were generated by MDA-MB-468 implantation into the 2nd and 4th mammary fat pads of athymic nude mice and treated with the virus. Results. Chimeric parapoxvirus (CF189) demonstrated dose-dependent cytotoxicity at low multiplicity of infection, with > 80% cell death 6 days after treatment. Significant reductions in tumor size were observed 2 weeks after intratumoral injection at doses as low as 10 3 plaque-forming units (PFU) compared with control (P < 0.01). In addition, abscopal effect (shrinkage of noninjected remote tumors) was clearly demonstrated. Conclusion. Chimeric parapoxvirus (CF189) demonstrated efficient cytotoxicity in vitro and potent antitumor effect in vivo at doses as low as 10 3 PFU. These are data encouraging of clinical development for this highly potent agent against triple-negative breast cancer.
Introduction
Approximately 12%-20% of 1 million newly diagnosed breast cancer cases worldwide each year are triple negative, 1 meaning they lack expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Triple-negative breast cancer (TNBC) demonstrates poorer clinical outcomes, both due to its inherently aggressive behavior and the lack of effective targeted therapies. Patients with TNBC are at a higher risk of relapse and development of metastatic disease in the first 5 years after diagnosis than non-TNBC patients. 2 Currently, the mainstay of adjuvant therapy for TNBC is cytotoxic chemotherapy, but intensive research and development of targeted therapies have been ongoing, including studies on poly (ADP-ribose) polymerase 1 (PARP1) inhibitors, PI3K inhibitors, MEK inhibitors and programmed cell death ligand 1 (PD-L1) inhibitors. 1, 3 Research and development of oncolytic viruses (OV) have increased significantly after US Food and Drug Administrationapproval of talimogene laherparepvec (T-VEC) as the first OV for use in humans. 4 This approval was a landmark event in the fields of virology and immunotherapeutics, spurring great interest in further development of OVs for the treatments of other cancers, including TNBC. OVs demonstrate a natural tropism for cancer cells compared with normal cells, exploiting pathologic derangements in cancer cells such as altered intracellular signaling pathways and overexpression of cell surface receptors to preferentially infect cancer cells. [5] [6] [7] Additionally, OV-mediated destruction of infected cells releases cytokines, tumor-associated antigens (TAA), damage-associated molecular pattern molecules (DAMPs), and pathogen-associated molecular pattern molecules (PAMPs) that prime both the innate and adaptive immune systems against cancer cells. and increased number of tumor-infiltrating lymphocytes (TILs) in the microenvironment. 13 This makes TNBC more immunogenic than non-triple-negative disease and an appealing candidate for OVdirected therapy. Our group has previously investigated an oncolytic vaccinia virus with antitumor effect in a TNBC model. 14 Here we present data on a novel chimeric parapoxvirus that is effective in TNBC models both in vitro and in vivo.
Methods

Cell culture and cell lines
Human TNBC cell lines MDA-MB-231 (kindly provided by Dr Sangkil Nam, City of Hope National Medical Center, Duarte, CA), MDA-MB-468 (kindly provided by Dr John Yim, City of Hope National Medical Center), BT549 (Dr Yim), and Hs578T (Dr Yim) were cultured in RPMI 1640 (Corning, Corning, NY) supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic solution. All TNBC cell lines were tested and verified as authentic by Genetica Cell Line Testing (Burlington, NC). African green monkey kidney fibroblasts (CV-1) and cow kidney epithelial cells (MDBK) were obtained from American Type Culture Collection (Manassas, VA) and cultured in Dulbecco's modified Eagle's medium (DMEM, Corning) supplemented with 10% FBS and 1% antibiotic-antimycotic solution. All cells were grown at 37°C in a 5% CO2-humidified incubator.
Development and selection of chimeric parapoxvirus
To generate a pool of chimeric parapoxviruses, MDBK cells were co-infected with orf virus strain NZ2 (ATCC) and pseudocowpox virus strain TJS (ATCC). Infected cells were harvested at 3 days after infection. From the MDBK cells infected with the chimeric parapoxvirus pool 100 chimeric parapoxvirus plaques were picked. These 100 plaques were further plaque-purified 2 more times in MDBK cells to yield 100 clonally purified individual chimeric virus isolates, which, together with its parental viruses, were subject to high-throughput screening in the NCI-60 cell lines. The isolate CF189 demonstrated the most potent tumoricidal properties against the NCI-60 cell lines and was chosen for this study.
Cytotoxicity assays
Cells were seeded at 1,000 cells/well for MDA-MB-231, BT549, and Hs578T and at 3,000 cells/well for MDA-MB-468 in 96-well plates and incubated overnight. Cells were infected with 0.1, 1, and 10 multiplicities of infection (MOI) of each virus for MDA-MB-231 and with 0.01, 0.1, and 1 MOI for MDA-MB-468, BT549, and Hs578T. Cell viability was measured in triplicate every 24 hours for 1 to 6 days using CellTiter 96 Aqueous One solution (Promega, Madison, WI) on a spectrophotometer (Tecan Spark 10M, Mannedorf, Switzerland) at 490 nm.
Viral replication assays
Viral replication in TNBC was quantified using standard plaque assay. Cells were plated to confluence in 6-well plates in 2-ml growth media and then infected with 0.01 MOI of each virus. Cells were harvested in triplicate for 3 consecutive days. MDBK cells were infected with serial dilutions of samples treated with CF189 in 24-well plates.
Orthotopic xenograft models
Twenty-six Hsd:Athymic Nude-Foxn1 nu female nude mice (Envigo, Indianapolis, IN) were injected with 10 7 MDA-MB-468 cells with 6-mg/ml matrigel (Corning) in the 2nd and 4th mammary fat pads at 12 weeks of age. When the tumors reached approximately 100-150 mm 3 in size, mice were randomized and tumors were injected intratumorally with either phosphate buffer saline (PBS) alone (n = 4), 10 3 PFU (n = 6), 10 4 PFU (n = 6) or 10 5 PFU (n = 7) in 50 μL PBS. Variance of tumor size did not differ significantly between the groups before treatment. Tumor size was then measured every 3 days for 6 weeks. Tumor volume was calculated according to V (mm
, where a is the smallest diameter and b is the largest diameter. Seven days after intratumoral injection, 2 to 4 mice per group were killed such that tumor and organs (lung, heart, liver, kidney, spleen, ovary, brain) were snap frozen in liquid nitrogen and used for further histopathologic staining, immunohistochemical staining and viral plaque assays. For the remaining 3 mice, only the 2nd mammary tumors were treated with 10 5 PFU in 50 μL PBS to observe the effect, if any, on the uninjected 4th mammary tumor. Two weeks after treatment, both tumors were harvested to determine viral titer in each.
Staining and imaging
Hematoxylin and eosin (H&E) staining of tissue sections was performed per routine protocols by our institutional pathology department, with selected slides reviewed by a veterinary pathologist at City of Hope. Tissue slides were stained for immunofluorescence with the primary antibody against orf virus at 1:50 dilution (LSBio, ORFV086, Seattle, WA). Slides were first blocked with tyramide signal amplification (TSA) blocking solution for 30 minutes. Primary antibody was incubated overnight at 4°C, serially washed in Tween, then incubated with the immunofluorescent secondary antibody for 60 minutes at room temperature (AlexaFluor 546, Thermo Fischer, Waltham, MA). Imaging was performed using Life Technologies EVOS FL Auto imaging system (Life Technologies, Carlsbad, CA). For natural killer (NK) cell staining, heatmediated antigen retrieval was performed using IHC-TEK Epitope Retrieval Solution (IHC World, Ellicott City, MD) following manufacturer's protocol. The sections were incubated with rat antiCD49b antibody (BioLegend, San Diego, CA) diluted 1:100 in TNB blocking buffer overnight in a humidified chamber at 4°C. Tumor sections were washed and incubated with horseradish peroxidase (HRP)-conjugated goat anti-rat antibody (Abcam, Cambridge, MA) for 60 minutes at room temperature, then treated for 10 minutes with the HRP substrate 3,3' Diaminobenzidine (DAB) (Abcam, Cambridge, MA) and counterstained with hematoxylin. Slides were then dehydrated and imaged using the widefield light microscope Zeiss Observer Z1 (Zeiss, Jena, Germany).
Results
CF189 effectively kills TNBC in vitro in a time-and dose-dependent manner
Given the heterogeneous nature of TNBC, 2 cell lines of metastatic origin (MDA-MB-231 and MDA-MB-468) and 2 cell lines of nonmetastatic origin (Hs578T and BT549) were treated with CF189 at MOI ranging 0.01-10 through 6 days. CF189 most efficiently killed Hs578T (LD50 at 96 hours: MOI 0.396) and MDA-MB-468 (LD50, MOI 0.185) with > 80% cell death at 6 days when treated with MOI 1 (Fig 1, A and C) . Although LD50 was higher for BT549 and MDA-MB-231 (LD50, MOI 1.636, and MOI 1.712, respectively), MDA-MB-231 data show that increasing the concentration of CF189 results in > 90% cell death at MOI 10 after 6 days (Fig 1, D) .
CF189 replicates in TNBC in vitro
Viral replication was assessed in all 4 TNBC cell lines by standard plaque assay of infected cells collected over 3 days. Efficient viral replication occurred in BT549, Hs578T, and MDA-MB-231 at MOI 0.01, with maximal replication occurring in the 24-48 hour period (Fig 2) . However, CF189 replication in MDA-MB-468 was poor at MOI 0.01 despite demonstrating effective cytotoxicity at low MOI. Viral replication was improved by increasing concentration to MOI 10 in the MDA-MB-468 line (Fig 2) . 
Intratumoral CF189 injection effectively reduces tumor size in orthotopic TNBC xenografts without significant viral toxicity
Orthotopic xenografts were created by implanting MDA-MB-468 cells into the 2nd and 4th mammary fat pads of athymic nude mice. Both tumors received a single intratumoral injection of either PBS or CF189 (10 3 PFU, 10 4 PFU, or 10 5 PFU). All groups treated with CF189 demonstrated significant reduction in relative tumor size by post-treatment day 13 compared with PBS-treated controls and this treatment effect was sustained 6 weeks postinjection (Fig 3, A) . Intratumoral injections were well tolerated without notable viral toxicity in the mice, as demonstrated by lack of significant body weight reduction in treatment groups compared with controls (Fig 3,  B) .
CF189 biodistribution at 1 week and 6 weeks post-treatment demonstrates inherent tumor-specificity in vivo
At 1 week and 6 weeks after CF189 injection, 2 -4 mice from each group were killed for viral biodistribution. Viral titers of infected tumor tissue demonstrated 2-log higher CF189 titer compared with other organs at both time points, reflecting CF189's natural tropism for cancer cells compared with normal cells (Table) . Apart from injected tumor tissue CF189 was only detected in heart and lung tissue 1 week postinjection and in lung tissue 6 weeks postinjection, which correlates with the lack of significant systemic toxicity observed. H&E-stained tissue from heart and lung specimens in the treatment group did not demonstrate evidence of cellular injury compared with control tissues on review by our veterinary pathologist.
Infection and replication of CF189 in orthotopic xenograft model confirmed by immunofluorescent imaging
At 1 week after CF189 injection, immunofluorescent detection of polyclonal antibody against orf virus demonstrated viral infection of tumor tissue treated with CF189 at 10 5 PFU per tumor compared with the control (Fig 4, A and B) . Furthermore, the pattern of antibody detection merged with 4',6-diamidino-2-phenlylindole (DAPI) counterstain is consistent with active replication in viral factories, as the orf virus antibodies (red) localize to areas just outside the nucleus (blue) (Fig 4, C) .
Virus-treated tumor tissue exhibits increased NK cell infiltration 1 week after CF189 treatment
Both control and treatment tumor tissue harvested 1 week and 6 weeks after CF189 were assessed for NK cell infiltration by incubation with a primary antibody against CD49b, followed by a secondary HRP-linked antibody. While no NK cells were visualized in the control tumor tissue (Fig 5, A) , NK cells were observed in the periphery of virus-treated tumor tissue after 1 week, suggesting that virus treatment stimulated an immune response against tumor in this period (Fig 5, B) . At 6-weeks posttreatment, no difference was observed between the number of NK cells in treatment and control groups (Fig 5, C and D, respectively) .
Intratumoral CF189 injection produces tumoristatic effect on distant uninjected tumors
We treated 3 animals with CF189 at 10 5 PFU in only the 2nd mammary tumor, while the 4th mammary tumor remained untreated. Tumor size was measured every 3 days in comparison with PBS-treated controls and viral titers were quantified by standard plaque assay at the end of 2 weeks. While relative tumor size increased initially in the injected tumor group (likely because of the trauma of the injection itself), tumor size decreased after day 6 with significant reduction compared with control by day 13 (P < 0.05). Relative tumor size of the uninjected tumor group remained stable despite never being directly treated with CF189 (Fig 6) . Viral titers at the end of 2 weeks showed the average titer of injected tumors was 3.37 × 10 3 PFU/g tissue compared with the average of uninjected tumors at 1.15 × 10 3 PFU/g tissue.
Discussion
Our data demonstrate that a novel chimeric parapoxvirus, CF189, has in vitro cytotoxic effects in 4 different TNBC cell lines, both of metastatic and nonmetastatic origin. Single intratumoral injec- tion of CF189 in athymic nude mice TNBC xenografts significantly reduced relative tumor size without signs of obvious toxicity. Furthermore, the virus was also detected at noninjected distant tumor sites with size stabilization of those tumors. Thus, CF189 demonstrates the ability to travel systemically and target distant sites of disease, which may have applications for neoadjuvant therapy and in metastatic settings. Given that TNBC tends to exhibit more aggressive behavior than receptor-positive disease and lacks wellcharacterized molecular targets for therapy, an oncolytic virus with natural tropism for TNBC cells with the ability to potentially target occult disease is an exciting prospect in the treatment of this challenging disease entity. Of note, in vivo reduction of tumor size was observed with CF189 doses as low as 10 3 PFU per tumor. This suggests that the antitumor effect is unlikely a result of direct oncolysis from viral replication, as CF189 demonstrated poor in vitro replication. Genetic sequencing of CF189 reveals close relationship to one of its parent viruses, the parapoxvirus orf virus (ORFV). Previous studies of ORFV have shown that ORFV treatment induces a strong immunomodulatory effect, particularly with regard to NK cell activation. 15, 16 Even treatment with ultraviolet-inactivated ORFV elicited similar, although weaker, response, suggesting that the virus itself likely harbors an antigenic structural component that is capable of inducing an immune response independent of its actual replication. Our staining results support the hypothesis that CF189 stimulates the innate immune system against tumor cells, providing an explanation of the effect seen at low dose and its poor replication in vitro. At the 1-week time point NK cells are observed at the periphery of the treated tumor tissue, but not in the control tumors. Of interest, at the 6-week time point, NK cells are noted in both the control and treatment tumors in similar density. This suggests that perhaps even in untreated mice, the immune system has some degree of response against tumor over time, and the initial effect of the single CF189 treatment has diminished. This correlates with the observation that, although tumor size is significantly reduced compared with control with this reduction in size stabilized during the duration of the study, continued reduction in tumor size does not continue beyond the 3rd postinjection week. In future works, this period would serve as an interesting time point to experiment with repeat dosing of CF189 to determine whether continued response can be induced toward complete tumor resolution.
In comparison towith other OVs, ORFV has not been well studied in the context of clinical therapeutics development. Much of what is known regarding its natural disease history has been gleaned from veterinary medicine. However, several properties of ORFV may be advantageous for developing it as an OV for the treatment of human cancers. First, ORVF infection does not cause serious diseases in humans. 17 Second, ORFV infection induces a potent immune system stimulation (Th1 dominated) and even inactivated viral particles retain the ability to induce an immune response. 18, 19 Third, neutralizing antibody is rare and reinfection can occur despite antibody production against ORFV. This means that repeated doses can potentially be given to the same patient, 16 a logistical improvement over other OVs in clinical development that require serotype switching or 2nd doses of antigenically unique viruses for continued response. Last, clinical response with the use of lower viral titers of ORFV is another practical improvement for OV development, as OV production is difficult, cost-and time-intensive, and typically requires titers in the range of 10 6 -10 9 PFU per injection. In summary, CF189 is a novel wild-type chimeric parapoxvirus effective against TNBC both in vitro and in vivo. With targeted therapies lacking for TNBC treatment, CF189 represents a promising avenue for immunotherapeutics in this field. In the future we will embark on further preclinical testing in other xenograft models, as well as genetic modifications to the wild-type virus to enhance tumor selectivity and overall potency.
